Una revisión para actualizar la práctica clínica | 09 OCT 20

Rosácea: lo que hay que saber

Enfermedad inflamatoria crónica de la piel que afecta principalmente las mejillas, la nariz, el mentón y la frente. Las manifestaciones incluyen eritema facial persistente, pápulas, pústulas, telangiectasias y sofocos recurrentes
Autor/a: Esther J. van Zuuren N Engl J Med 2017;377:1754-64
INDICE:  1. Página 1 | 2. Referencias bibliográficas
Referencias bibliográficas

1. van Zuuren EJ, Fedorowicz Z, Carter B, van der Linden MM, Charland L. Interventions for rosacea. Cochrane Database Syst Rev 2015; 4: CD003262.

2. Vieira AC, Mannis MJ. Ocular rosacea: common and commonly missed. J Am Acad Dermatol 2013; 69: Suppl 1: S36-S41.

3. Halioua B, Cribier B, Frey M, Tan J. Feelings of stigmatization in patients with rosacea. J Eur Acad Dermatol Venereol 2017; 31: 163-8.

4. Bewley A, Fowler J, Schofer H, Kerrouche N, Rives V. Erythema of rosácea impairs quality of life: results of a metaanalysis. Dermatol Ther (Heidelb) 2016; 6:237-47.

5. Egeberg A, Hansen PR, Gislason GH, Thyssen JP. Patients with rosacea have increased risk of depression and anxiety disorders: a Danish nationwide cohort study. Dermatology 2016; 232: 208-13.

6. Elewski BE, Draelos Z, Dreno B, Jansen T, Layton A, Picardo M. Rosacea — global diversity and optimized outcome: proposed international consensus from the Rosacea International Expert Group. J Eur Acad Dermatol Venereol 2011; 25: 188-200.

7. Tan J, Berg M. Rosacea: current state of epidemiology. J Am Acad Dermatol 2013; 69: Suppl 1: S27-S35.

8. Wilkin J, Dahl M, Detmar M, et al. Standard classification of rosacea: report of the National Rosacea Society Expert Committee on the classification and staging of rosacea. J Am Acad Dermatol 2002; 46: 584-7.

9. Tan J, Almeida LM, Bewley A, et al. Updating the diagnosis, classification and assessment of rosacea: recommendations from the global ROSacea COnsensus (ROSCO) panel. Br J Dermatol 2017; 176: 431-8.

10. Picardo M, Eichenfield LF, Tan J. Acne and rosacea. Dermatol Ther (Heidelb) 2017; 7: Suppl 1: 43-52.

11. Two AM, Wu W, Gallo RL, Hata TR. Rosacea: part I. Introduction, categorization, histology, pathogenesis, and risk factors. J Am Acad Dermatol 2015; 72: 749-58.

12. Steinhoff M, Schauber J, Leyden JJ. New insights into rosacea pathophysiology: a review of recent findings. J Am Acad Dermatol 2013; 69: Suppl 1: S15-S26.

13. Del Rosso JQ, Thiboutot D, Gallo R, et al. Consensus recommendations from the American Acne & Rosacea Society on the management of rosacea, part 1: a status report on the disease state, general measures, and adjunctive skin care. Cutis 2013; 92: 234-40.

14. Two AM, Wu W, Gallo RL, Hata TR. Rosacea: part II. Topical and systemic therapies in the treatment of rosacea. J Am Acad Dermatol 2015; 72: 761-70.

15. Schaller M, Almeida LM, Bewley A, et al. Rosacea treatment update: recommendations from the global ROSacea COnsensus (ROSCO) panel. Br J Dermatol 2017; 176: 465-71.

16. Powell FC. Rosacea. N Engl J Med 2005; 352: 793-803.

17. Reinholz M, Tietze JK, Kilian K, et al. Rosacea — S1 guideline. J Dtsch Dermatol Ges 2013; 11: 768-80.

18. Asai Y, Tan J, Baibergenova A, et al. Canadian clinical practice guidelines for rosacea. J Cutan Med Surg 2016; 20: 432-45.

19. Schunemann H, Brożek J, Guyatt G, Oxman A, eds. GRADE [Grading of recommendations, Assessment, Development and Evaluation] handbook. October 2013 (http://www .guidelinedevelopment .org/handbook).

20. Fowler J Jr, Jackson M, Moore A, et al. Efficacy and safety of once-daily topical brimonidine tartrate gel 0.5% for the treatment of moderate to severe facial erythema of rosacea: results of two randomized, double-blind, and vehicle-controlled pivotal studies. J Drugs Dermatol 2013; 12: 650-6.

21. Rhofade cream prescribing information. Irvine, CA: Allergan, 2017 (https:/ /www .allergan .com/assets/pdf/rhofade_pi.pdf ).

22. Stein L, Kircik L, Fowler J, et al. Efficacy and safety of ivermectin 1% cream in treatment of papulopustular rosacea: results of two randomized, double-blind, vehicle-controlled pivotal studies. J Drugs Dermatol 2014; 13: 316-23.

23. Draelos ZD, Elewski B, Staedtler G, Havlickova B. Azelaic acid foam 15% in the treatment of papulopustular rosacea: a randomized, double-blind, vehicle-controlled study. Cutis 2013; 92: 306-17.

24. Beutner K, Calvarese B. A multi-center, investigator-blind clinical trial to assess the safety and efficacy of metronidazole gel 1% as compared to metronidazole gel vehicle and metronidazole cream 1% in the treatment of rosacea. J Am Acad Dermatol 2005; 52(3): Suppl 10. abstract.

25. Bitar A, Bourgouin J, Dore N, et al. A double-blind randomised study of metronidazole (Flagyl) 1% cream in the treatment of acne rosacea. Drug Invest 1990; 2: 242-8.

26. Bjerke JR, Nyfors A, Austad J, et al. Metronidazole (Elyzol) 1% cream v. placebo cream in the treatment of rosacea. Clin Trials J 1989; 26: 187-94.

27. Bleicher PA, Charles JH, Sober AJ. Topical metronidazole therapy for osacea. Arch Dermatol 1987; 123: 609-14.

28. Breneman DL, Stewart D, Hevia O, Hino PD, Drake LA. A double-blind, multicenter clinical trial comparing efficacy of once-daily metronidazole 1 percent cream to vehicle in patients with rosacea. Cutis 1998; 61: 44-7.

 

Comentarios

Para ver los comentarios de sus colegas o para expresar su opinión debe ingresar con su cuenta de IntraMed.

AAIP RNBD
Términos y condiciones de uso | Todos los derechos reservados | Copyright 1997-2021